Less is More: Benefit of Achieving Very Low Low-Density Lipoprotein-Cholesterol Levels on Cardiovascular Events
DOI:
https://doi.org/10.17140/HROJ-4-134Abstract
Low-density lipoprotein-cholesterol (LDL-C) reduction with statin therapy is one of
the most pivotal interventions for atherosclerotic cardiovascular disease (ASCVD) prevention
and treatment. The risk of coronary artery disease (CAD) decreases with reduction in LDL-C
but there is no established level at which the risk becomes insignificant. The current practice
guidelines for the primary prevention of CAD recommends calculation of ASCVD risk instead
of targeting a particular cholesterol level for initiating statin therapy.1,2 It is recommended that
patients with known CAD or those presenting with acute coronary syndromes (ACS) receive
high intensity statin independent of baseline LDL-C levels. However, the target LDL-C goal
for secondary prevention of CAD remains unclear. Besides reducing LDL-C, statins also have
pleiotropic effects, such as lowering inflammation and stabilizing atherosclerotic plaques
References
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2): S46-S48. doi: 10.1161/01.cir.0000437738.63853.7a
Keaney JF Jr, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014; 370(3): 275-278. doi: 10.1056/NEJMms1314569
Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation. 2004; 109(21 Suppl 1): II18-II26. doi: 10.1161/01. CIR.0000129505.34151.23
Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005; 46(8): 1411-1416. doi: 10.1016/j.jacc.2005.04.064
Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-den-sity lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JU-Heart Res Open J PITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). J Am Coll Car-diol. 2011; 57(16): 1666-1675. doi: 10.1016/j.jacc.2010.09.082
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe add-ed to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489
Jarcho JA, Keaney JF Jr. Proof that lower is better-LDL cho-lesterol and IMPROVE-IT. N Engl J Med. 2015; 372(25): 2448- 2450. doi: 10.1056/NEJMe1507041
Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol. 2015; 65(24): 2638-2651. doi: 10.1016/j.jacc.2015.05.001
Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial. Am Heart J. 2016; 173: 94-101. doi: 10.1016/j.ahj.2015.11.015
Schwartz GG, Bessac L, Berdan LG, et al. Effect of ali-rocumab, a monoclonal antibody to PCSK9, on long-term car-diovascular outcomes following acute coronary syndromes: Ra-tionale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168(5): 682-689. doi: 10.1016/j.ahj.2014.07.028
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.